TABLE 1 | Selected agents in development for type 1 diabetes

From the following article:

Type 1 diabetes

Paul Burn

Nature Reviews Drug Discovery 9, 187-188 (March 2010)


DrugCompanyPropertiesPatient populationTrial phase
TeplizumabMacroGenics/Eli LillyCD3-specific mAbNewly diagnosedIII
OtelixizumabTolerx/GlaxoSmithKlineCD3-specific mAbNewly diagnosedIII
Alum-formulated GADDiamyd Medical ABGAD65-based vaccineNewly diagnosedIII
DiaPep277Andromeda BiotechHSP60-derived peptideNewly diagnosedIII
BHT-3021Bayhill Therapeutics/GenentechDNA plasmid encoding pro-insulinNewly diagnosedI/II
TT-223 and GLP1Transition Therapeutics/Eli LillyGastrin and GLP1Newly diagnosedI/II
ProchymalOsiris Therapeutics/GenzymeMesenchymal stem cellsNewly diagnosedI/II
INGAP peptideExsulin Corporation15 amino-acid sequence in INGAPEstablishedI/II
GAD65, glutamate decarboxylase 65 kDa isoform (also known as GAD2); GLP1, glucagon-like peptide 1; HSP60, heat-shock protein 60; INGAP, islet neogenesis associated protein; mAb, monoclonal antibody.

Download file

If the slide opens in your browser, select "File > Save As" to save it.